廣生堂(300436.SZ)：在研創新藥獲得專利證書或授權通知書
格隆匯11月18日丨廣生堂(300436.SZ)公佈，近日，公司獲得了在研創新藥的專利證書或授權通知書，現公吿如下：
新型c-Met靶向藥物GST-HG161獲得印度尼西亞、新西蘭、南非專利授權通知書和哥倫比亞專利證書
公司新型c-Met 靶向藥物GST-HG161的系列化合物已通過PCT 途徑申請國際專利，且已獲得中國、美國、歐洲、加拿大、日本、澳大利亞等16個國家或地區的化合物發明專利授權。
乙肝治療創新藥GST-HG141獲得中國台灣專利證書。
公司乙肝治療創新藥GST-HG141的系列化合物已通過PCT途徑申請國際專利，且已獲得中國、美國、歐洲、日本、韓國、加拿大、澳大利亞等15個國家或地區的化合物發明專利授權。
乙肝治療創新藥GST-HG131、GST-HG121獲得巴西、中國台灣專利授權通知書
公司乙肝治療創新藥GST-HG131、GST-HG121的系列化合物已通過 PCT途徑申請國際專利，其中，GST-HG131 已獲得中國、中國香港、中國澳門的化合物發明專利授權和中國台灣的晶型發明專利，GST-HG121已獲得美國、中國、歐洲、日本、加拿大、韓國等14個國家或地區的化合物發明專利授權。
非酒精性脂肪肝病及肝纖維化可逆轉新藥GST-HG151 獲得印度尼西亞專利授權通知書
公司非酒精性脂肪肝病及肝纖維化可逆轉新藥GST-HG151的系列化合物已通過PCT途徑申請國際專利，且已獲得中國、美國、歐洲、澳大利亞、日本、韓國、南非、加拿大、馬來西亞、墨西哥等15個國家或地區的化合物發明專利授權，另外，也已取得中國台灣的晶型發明專利授權。
創新藥發明專利的授權與取得有利於公司完善知識產權保護體系，發揮自主知識產權優勢，提升核心競爭力。上述創新藥獲得專利證書或授權通知書不會對公司生產經營產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
